Core Viewpoint - PPL Corporation is expected to report strong quarterly earnings, with a significant year-over-year increase in earnings per share, driven by various operational efficiencies and market demand [1][3]. Financial Performance - The company is projected to report earnings per share of $0.42 and revenue of approximately $2.42 billion [1][6]. - The expected earnings per share reflects a year-over-year increase of 23.53% [3]. Analyst Sentiment - Wall Street analysts have a bullish outlook on PPL, with an average brokerage recommendation (ABR) of 1.66, indicating a favorable view [2][6]. - Out of 16 brokerage firms, 10 have rated PPL as a Strong Buy, and one has given it a Buy rating, suggesting strong potential in PPL's stock [2]. Valuation Concerns - PPL's forward price-to-earnings ratio is 19.16, which is higher than the industry average of 17.17, indicating a premium valuation [4]. - The company's return on equity (ROE) stands at 9.08%, which is below that of its peers, potentially impacting investor sentiment [4]. Earnings Surprise History - Historically, PPL has had a mixed earnings surprise record, beating the Zacks Consensus Estimate in two of the last four quarters, resulting in a negative average surprise of 1.02% [5].

While reporting financial results for the first quarter on Wednesday, semiconductor company Analog Devices, Inc. (ADI) provided earnings and revenue guidance for the second quarter of fiscal 2026.For the second quarter, the company projects earnings in a range of $2.04 to $2.34 per share and adjusted earnings in a range of $2.73 to $3.03 per share on projected revenues between $3.4 billion and $3.60 billion.The company's Board of Directors declared an 11 percent higher quarterly cash dividend of $1.10 per ...

Wall Street analysts expect Savers Value Village (SVV) to post quarterly earnings of $0.16 per share in its upcoming report, which indicates a year-over-year increase of 60%. Revenues are expected to be $464.69 million, up 15.6% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings release, it is of utmost ...

Core Insights - Wall Street analysts expect Universal Display Corp. (OLED) to report quarterly earnings of $1.28 per share, reflecting a year-over-year increase of 4.9% [1] - Revenues are projected to be $173.25 million, which is a 6.8% increase from the same quarter last year [1] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analysts' projections [1] Revenue Breakdown - Analysts estimate 'Revenue- Material sales' will reach $95.47 million, representing a 2.4% increase from the prior-year quarter [4] - 'Revenue- Contract research services' is expected to be $5.46 million, indicating an 18.3% increase from the prior-year quarter [4] - 'Revenue- Royalty and license fees' is projected to arrive at $72.31 million, reflecting a 12.3% increase from the year-ago quarter [5] Market Performance - Universal Display shares have shown a return of +7.4% over the past month, contrasting with the Zacks S&P 500 composite's -1.7% change [5] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [5]

Wall Street analysts forecast that Walmart (WMT) will report quarterly earnings of $0.73 per share in its upcoming release, pointing to a year-over-year increase of 10.6%. It is anticipated that revenues will amount to $189.99 billion, exhibiting an increase of 5.2% compared to the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projec ...

Core Viewpoint - Analysts project that Carvana (CVNA) will report quarterly earnings of $1.10 per share, reflecting a 96.4% year-over-year increase, with revenues expected to reach $5.19 billion, a 46.3% increase from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been adjusted upward by 0.6% over the past 30 days, indicating a reassessment by analysts [1][2]. - Changes in earnings projections are crucial for predicting investor reactions and short-term stock price movements [2]. Revenue Estimates - Analysts estimate 'Sales and operating revenues - Retail vehicle sales, net' to be $3.80 billion, a 48.9% increase from the prior-year quarter [4]. - 'Sales and operating revenues - Other sales and revenues' is projected at $434.07 million, reflecting a 36.9% increase from the previous year [4]. - 'Sales and operating revenues - Wholesale sales and revenues' is expected to reach $945.49 million, a 39.5% increase year-over-year [5]. Unit Sales and Profit Metrics - 'Unit sales - Retail vehicle unit sales' are forecasted to be 157,216, compared to 114,379 in the same quarter last year [6]. - 'Per retail unit gross profit - Total' is expected to be $6,780.51, up from $6,671.00 in the same quarter last year [5]. - 'Per retail unit gross profit - Retail vehicle' is projected at $3,198.55, slightly down from $3,226.00 year-over-year [6]. Additional Revenue Insights - 'Per unit revenue - Wholesale vehicles' is estimated at $10,326.34, compared to $9,371.00 in the same quarter last year [7]. - 'Per unit revenue - Retail vehicles' is expected to reach $24,019.17, up from $22,312.00 in the previous year [8]. - 'Unit sales - Wholesale vehicle unit sales' are projected at 67,233, compared to 48,770 in the same quarter last year [8]. Market Metrics - The estimated 'Markets at end of period (metropolitan statistical areas)' remains at 316, unchanged from the previous year [9]. - The average prediction for 'Per retail unit gross profit - Wholesale' is $586.51, down from $674.00 year-over-year [9]. - Carvana shares have decreased by 20.6% in the past month, contrasting with a -0.3% change in the Zacks S&P 500 composite [9].

Core Insights - Wall Street analysts forecast Kinross Gold (KGC) will report quarterly earnings of $0.54 per share, reflecting a year-over-year increase of 170% [1] - Anticipated revenues for the quarter are projected to be $1.87 billion, representing a 32.4% increase compared to the same quarter last year [1] Earnings Projections - Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 38.3%, indicating a collective reassessment by covering analysts [2] - Changes in earnings projections are crucial for predicting investor reactions to the stock, with empirical studies showing a strong correlation between earnings estimate trends and short-term stock price movements [3] Key Metrics - Analysts estimate the 'Production cost of sales per equivalent ounce sold' to be $1,263, up from $1,098 reported in the same quarter last year [5] - The consensus for 'Gold equivalent ounces - Produced - Operations Total' is expected to be 464 million ounces, down from 514 million ounces in the previous year [5] - The estimated 'Attributable all-in sustaining cost per equivalent ounce sold' is projected at $1.79 billion, compared to $1.51 billion a year ago [6] Stock Performance - Kinross Gold shares have increased by 4.6% over the past month, contrasting with a -0.3% change in the Zacks S&P 500 composite [6] - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [6]

Core Viewpoint - Analysts project that Edwards Lifesciences will report quarterly earnings of $0.62 per share, reflecting a year-over-year increase of 5.1%, with revenues expected to reach $1.54 billion, an 11.1% increase from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been revised upward by 0.7% in the past 30 days, indicating a reassessment of initial estimates by covering analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Key Metrics Estimates - Analysts estimate 'Net Sales by Product Group - Transcatheter Mitral and Tricuspid Therapies' will reach $151.63 million, a 44.3% increase year-over-year [5]. - The consensus for 'Net Sales by Product Group - Surgical Structural Heart' is $259.76 million, suggesting a 6.3% year-over-year change [5]. - 'Net Sales by Product Group - Transcatheter Aortic Valve Replacement' is projected at $1.13 billion, reflecting an 8.9% increase from the previous year [6]. - 'Net Sales - Europe' is estimated at $385.24 million, indicating a 12.1% year-over-year change [6]. - 'Net Sales - Outside of the United States' is expected to be $656.66 million, a 14.6% increase year-over-year [7]. - 'Net Sales - United States' is projected at $881.08 million, reflecting an 8.4% increase from the year-ago quarter [7]. - 'Net Sales - Japan' is estimated to reach $92.30 million, indicating a 7.5% year-over-year change [7]. - 'Net Sales - Rest of World' is projected at $179.12 million, reflecting a 25% increase from the previous year [8]. Stock Performance - Edwards Lifesciences shares have decreased by 6% over the past month, contrasting with the Zacks S&P 500 composite's increase of 0.5%, and the company holds a Zacks Rank 3 (Hold), suggesting it will closely follow overall market performance in the near term [8].

Core Viewpoint - Elevance Health (ELV) is expected to report a quarterly earnings per share (EPS) of $3.07, reflecting a decline of 20.1% year-over-year, while revenues are forecasted to increase by 10.1% to $49.53 billion [1]. Earnings Estimates - The consensus EPS estimate has been revised 0.2% lower in the last 30 days, indicating a reevaluation by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and stock price performance [3]. Revenue Projections - Analysts predict 'Revenues- Service fees' at $2.13 billion, a year-over-year increase of 4.7% [5]. - 'Revenues- Premiums' are estimated at $40.69 billion, reflecting a 12.3% year-over-year increase [5]. - 'Revenues- Net investment income' is expected to reach $469.69 million, indicating a decline of 10.9% year-over-year [5]. - 'Revenues- Product revenue' is projected at $6.82 billion, a 1.5% year-over-year increase [6]. Membership Metrics - Total Medical Membership is projected to be 45.40 million, down from 45.73 million in the same quarter last year [6]. - 'Medical Membership - Medicare - Medicare Advantage' is estimated at 2.24 million, up from 2.07 million year-over-year [7]. - 'Medical Membership - Medicaid' is expected to be 8.60 million, down from 8.92 million year-over-year [7]. - 'Medical Membership - Federal Employees Health Benefits' is projected at 1.63 million, slightly down from 1.66 million year-over-year [8]. - Total Medicare membership is expected to reach 3.11 million, up from 2.96 million year-over-year [8]. - 'Medical Membership - Commercial Risk-Based - Individual' is estimated at 1.33 million, up from 1.29 million year-over-year [9]. - 'Benefit Expense Ratio' is forecasted to be 93.4%, compared to 92.4% year-over-year [9]. - 'Medical Membership - Commercial Fee-Based' is expected to be 27.08 million, down from 27.20 million year-over-year [9]. Stock Performance - Elevance Health shares have returned +8.4% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change [10]. - The company holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market [10].

Core Viewpoint - Analysts project that CSX will report quarterly earnings of $0.41 per share, reflecting a 2.4% decline year over year, with revenues expected to be $3.54 billion, indicating no change from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 3.9% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue Estimates - Analysts forecast 'Revenue- Coal' to reach $481.51 million, a decrease of 3.5% year over year [5]. - 'Revenue- Intermodal' is expected to be $554.16 million, reflecting a year-over-year increase of 5.4% [5]. - 'Revenue- Merchandise- Fertilizers' is projected at $137.18 million, indicating a 9.7% increase year over year [5]. - 'Revenue- Merchandise- Chemicals' is estimated to be $698.20 million, showing a decline of 1.4% from the prior year [6]. Operating Metrics - The estimated 'Operating Margin' is projected to be 67.2%, significantly higher than the year-ago figure of 31.3% [6]. - 'Revenue per unit - Intermodal' is expected to be $707.85, slightly up from $705.00 in the same quarter last year [6]. Volume Estimates - 'Volume - Merchandise - Automotive' is expected to be 92.58 thousand, down from 96.00 thousand year over year [7]. - 'Volume - Merchandise - Minerals' is projected at 87.05 thousand, compared to 88.00 thousand last year [7]. - 'Volume - Coal' is estimated at 180.65 thousand, slightly up from 179.00 thousand in the previous year [7]. - 'Volume - Merchandise - Fertilizers' is expected to reach 47.64 thousand, an increase from 44.00 thousand year over year [8]. - 'Volume - Merchandise - Metals and Equipment' is projected at 63.03 thousand, consistent with last year's figure of 63.00 thousand [8]. - 'Volume - Merchandise - Agricultural and Food Products' is estimated at 115.31 thousand, down from 116.00 thousand year over year [9]. Stock Performance - CSX shares have returned -0.9% over the past month, contrasting with the Zacks S&P 500 composite's +2% change, and the company holds a Zacks Rank 3 (Hold), indicating it is expected to mirror overall market performance [9].